Your session is about to expire
← Back to Search
Procedure
Microwave Ablation of Primary and Secondary Lung Malignancies
Phase 1 & 2
Waitlist Available
Led By Stefan J Przybojewski, MB ChB
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month post treatment
Awards & highlights
No Placebo-Only Group
Summary
This study is evaluating whether a surgery which reduces blood flow in a stomach artery leads to significant weightloss.
Eligible Conditions
- Solid Tumors
- Lung Cancer
- Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 month post treatment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month post treatment
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Efficacy of microwave ablation of lung lesions
Rate of adverse outcomes following microwave ablation
Rate of technical success
Secondary study objectives
Re-treatment rate.
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Microwave AblationExperimental Treatment1 Intervention
Study participants will receive percutaneous microwave ablation of their malignant lung neoplasm.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Microwave ablation
2011
N/A
~660
Find a Location
Who is running the clinical trial?
University of CalgaryLead Sponsor
810 Previous Clinical Trials
886,259 Total Patients Enrolled
Stefan J Przybojewski, MB ChBPrincipal InvestigatorUniversity of Calgary